We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MERCAPTOPURINE-LINK (Link Medical Products Pty Ltd)
Product name
MERCAPTOPURINE-LINK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
152 working days (255)
Active ingredients
mercaptopurine monohydrate
Registration type
New generic medicine
Indication
MERCAPTOPURINE-LINK (tablets) is indicated for the treatment of acute leukaemia. It is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukaemia and acute myelogenous leukaemia. MERCAPTOPURINE-LINK is also used in the treatment of chronic granulocytic leukaemia.